November 20, 2025 — Leads & Copy — SeaStar Medical Holding Corporation (Nasdaq: ICU) CEO Eric Schlorff will present at NobleCon21, Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference, on Wednesday, December 3rd at 4:00 pm EST. The event is being held at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida.
Investors and guests of SeaStar Medical are welcome to attend the conference. Registration is available here using the code ICUNOBLECON for the SeaStar Medical participation rate.
A replay of the presentation will be available on the company’s website on Thursday, December 4th after 4:00 pm EST. The replay will be available for up to 30 days following its posting.
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure. Its QUELIMMUNE (SCD-PED) therapy, based on its patented Selective Cytopheretic Device (SCD) technology, was approved in 2024 by the FDA. It is the only FDA-approved product for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients.
The FDA has granted Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy for six therapeutic indications, potentially expediting approval and improving reimbursement. The company is conducting a pivotal trial of its SCD therapy in adult AKI patients requiring continuous renal replacement therapy (CRRT), a condition with no effective treatment options that affects over 200,000 adults in the U.S. annually.
SeaStar Investor Relations:
IR@SeaStarMed.com
Source: SeaStar Medical
